KE

Keylika

YC S22

San Francisco, US · Founded 2022 · 1 employees · 1 known investors

keylika.com ↗

Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.

Founders & leadership· Y Combinator alumni (S22)

Buddha Chaudhuriin𝕏Founder

Frederik CeyssensinFounder

BP

Buddhadev P. Chaudhuri, PhDCEO & Co-Founder

FC

Frederik Ceyssens, PhDCTO & Co-Founder

Investors · 1

Y

Y CombinatorMountain View · $500K – $500K